1. Home
  2. ELUT vs CRBU Comparison

ELUT vs CRBU Comparison

Compare ELUT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELUT
  • CRBU
  • Stock Information
  • Founded
  • ELUT 2015
  • CRBU 2011
  • Country
  • ELUT United States
  • CRBU United States
  • Employees
  • ELUT N/A
  • CRBU N/A
  • Industry
  • ELUT Medical Specialities
  • CRBU Medicinal Chemicals and Botanical Products
  • Sector
  • ELUT Health Care
  • CRBU Health Care
  • Exchange
  • ELUT Nasdaq
  • CRBU Nasdaq
  • Market Cap
  • ELUT 94.0M
  • CRBU 93.0M
  • IPO Year
  • ELUT 2020
  • CRBU 2021
  • Fundamental
  • Price
  • ELUT $2.08
  • CRBU $0.77
  • Analyst Decision
  • ELUT Strong Buy
  • CRBU Strong Buy
  • Analyst Count
  • ELUT 2
  • CRBU 5
  • Target Price
  • ELUT $8.00
  • CRBU $10.60
  • AVG Volume (30 Days)
  • ELUT 38.7K
  • CRBU 1.0M
  • Earning Date
  • ELUT 05-08-2025
  • CRBU 05-08-2025
  • Dividend Yield
  • ELUT N/A
  • CRBU N/A
  • EPS Growth
  • ELUT N/A
  • CRBU N/A
  • EPS
  • ELUT N/A
  • CRBU N/A
  • Revenue
  • ELUT $23,711,000.00
  • CRBU $9,918,000.00
  • Revenue This Year
  • ELUT $39.35
  • CRBU N/A
  • Revenue Next Year
  • ELUT $61.26
  • CRBU $163.34
  • P/E Ratio
  • ELUT N/A
  • CRBU N/A
  • Revenue Growth
  • ELUT N/A
  • CRBU N/A
  • 52 Week Low
  • ELUT $1.79
  • CRBU $0.66
  • 52 Week High
  • ELUT $5.24
  • CRBU $4.21
  • Technical
  • Relative Strength Index (RSI)
  • ELUT 43.18
  • CRBU 43.66
  • Support Level
  • ELUT $1.79
  • CRBU $0.73
  • Resistance Level
  • ELUT $2.44
  • CRBU $0.91
  • Average True Range (ATR)
  • ELUT 0.22
  • CRBU 0.08
  • MACD
  • ELUT 0.00
  • CRBU 0.01
  • Stochastic Oscillator
  • ELUT 46.27
  • CRBU 24.34

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Share on Social Networks: